<DOC>
	<DOC>NCT03058822</DOC>
	<brief_summary>A Phase 1, relative bioavailability study of BMS-931699 from prefilled syringe compared to drug in vial</brief_summary>
	<brief_title>Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms, and clinical laboratory determinations All participants must have hemoglobin, hematocrit, and platelets within normal limits at screening All participants must have activated partial thromboplastin time, prothrombin time, and international normalized ratio within normal limits at screening Any current or past history or risk for tuberculosis: Active tuberculosis requiring treatment within the previous 3 years. All participants will be required to have a QuantiFERON tuberculosis Gold or TSPOT tuberculosis test performed at screening. Also excluded are participants with evidence of a past tuberculosis infection without documented adequate therapy. Participants with a positive QuantiFERON tuberculosis Gold or TSPOT tuberculosis test at screening will not be eligible for the study. A QuantiFERON tuberculosis Gold or TSPOT tuberculosis test performed within 4 weeks of dosing on Day 1 is acceptable as long as there is documentation of a negative result. Current clinical, radiographic, or laboratory evidence of active tuberculosis A history of herpes zoster</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>